Fintel reports that on November 18, 2024, BTIG initiated coverage of VYNE Therapeutics (NasdaqCM:VYNE) with a Buy ...

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target VYNE is pioneering the development of BET inhibitors in large inflammation and immunology, or I&I, ...

A GRADE II listed 18th-century wall at The Vyne will have its gate repaired and restored using the original materials. An ...

NASDAQ:VYNE opened at $3.16 on Friday. The firm has a market capitalization of $46.61 million, a PE ratio of -1.22 and a beta of 1.32. The stock’s fifty day moving average is $2.17 and its 200 ...

The trial was initiated in June 2024 and VYNE expects to report top-line results from the 24-week double-blind portion of the trial in mid-2025. The Phase 2b trial (NCT06493578) is a randomized ...

Shares of Richardson Electronics, Ltd. (NASDAQ: RELL) fell sharply in today’s pre-market trading after the company posted weaker-than-expected results for its second quarter. U.S. stocks traded ...

"A special thanks to Vyne Dental for providing me with the tools that I need to keep our office running efficiently and with ease. Thank you for making this award possible." Vyne Dental provides ...

BTIG initiated coverage of VYNE Therapeutics (VYNE) with a Buy rating and $8 price target Don't Miss our Black Friday Offers: Discover the latest stocks recommended by top Wall Street analysts, all in ...

The trial was initiated in June 2024 and VYNE expects to report top-line results from the 24-week double-blind portion of the trial in mid-2025. The Phase 2b trial (NCT06493578) is a randomized, ...

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025 Reported positive first-in-human Phase 1a SAD data ...